Importantly, plasma SAA increased with the COPD I-III stage of severity [18], and although these results may have been biased by the potentially altered inflammatory status of the lung parenchyma (obtained from COPD patients undergoing surgery for lung cancer), these findings support the role of SAA as an inflammatory marker in stable COPD. The gene discussed is SAA2; the disease is lung carcinoma.